Abstract 1222P
Background
Androgen-receptor splice variant 7 (AR-V7) is constitutively activated isoform of AR and has been associated with resistance towards AR targeting therapies and development into mCRPC. Confirmation of AR-V7 expression is important step in prostate cancer diagnosis and determining the drug, but the detection of AR-V7 with tissues has limitations such as clinical challenge to poorly accessible tumor tissues before and after treatment. Here, we developed the method of AR-V7 detection in circulating tumor cells (CTC) after isolation with CytoGen’s Smart BiopsyTM CTC isolator by in vitro assay of qRT-PCR with high sensitivity and specificity, overcoming the limitations of tissue biopsy.
Methods
Nested qPCR method was developed for high sensitivity and specificity of detection of AR-V7. Sensitivity and specificity were tested using AR-V7 positive cells (VCaP) and negative cells (PC-3 and Raji cells). Limit of detection of AR-V7 of nested PCR was performed with VCaP (200 cells to 20 cells, 4 points) mixed with Raji cells (1x10ˆ5cells). Then, VCaP cells (200 cells to 20 cells, 4 points) was spiked into peripheral blood mononuclear cells of blood sample (5mL, healthy donor) to mimic CTC after isolation by CytoGen’s Smart BiopsyTM CTC isolator, subsequently nested qPCR was carried out to detect of AR-V7 using each primer pairs. Non clinical sample were used.
Results
As a result of LoD test, AR-V7 expression was clearly detected even in the smallest VCaP sample and was not detected at all in the negative controls. The same clear result was also observed in the spiking test of VCaP into PBMCs isolated by CytoGen’s Smart BiopsyTM CTC isolator, suggesting that clinical samples of prostate cancer could be applied with excellent sensitivity and specificity for AR-V7.
Conclusions
AR-V7 expresses only a part of cancer tissue, so it is difficult to accurately diagnose with traditional histological assays. Detection of AR-V7 in intact live CTC isolated by CytoGen’s Smart BiopsyTM CTC isolator might overcome limitations of tissue biopsy. In this study, we developed a novel method of detection of AR-V7 in CTC with high sensitivity and specificity by in vitro assay and clinical test will be conducted for validation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cytogen. Inc.
Funding
Cytogen. Inc.
Disclosure
H. Kang, J.H. Lee, S. Kim, J.B. Lee, S. Park, J. Choi, H. Lee, J.W. Kim: Financial Interests, Personal, Full or part-time Employment: Cytogen, Inc.
Resources from the same session
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
1242P - Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Presenter: Dörthe Schaffrin-Nabe
Session: Poster session 14
1243P - Ocular surface squamous neoplasia early diagnosis using an AI-empowered autofluorescence multispectral imaging technique
Presenter: Abbas HABIBALAHI
Session: Poster session 14
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1245P - A lymph nodal staging assessment model for various histologic types of small intestinal tumors
Presenter: YOUSHENG LI
Session: Poster session 14
1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Presenter: Juan Blanco Heredia
Session: Poster session 14
1247P - A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
Presenter: Yunpeng Yang
Session: Poster session 14
1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection
Presenter: Jason Zhang
Session: Poster session 14
1249P - Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
Presenter: Jeffrey van Putten
Session: Poster session 14
1250P - Assessing lung carcinoma: A retrospective study on volume evaluation, consolidation and infiltration using chest OMX
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14